Objective: To explore the effects of vitamin D supplementation on bone metabolism of sodium valproate in the treatment of children with epilepsy

so as to provide reference for the treatment of epilepsy in children. Methods: Sixty children with epilepsy admitted into our hospital from Jun. 2015 to Jun. 2018 were extracted to be divided into the combination group and the control group via the random number table

with 60 cases in each group. The control group was treated with sodium valproate

while the combination group additionally received vitamin D supplementation on the basis of the control group. Changes of bone metabolism indicators of two groups were compared and analyzed before treatment and after treatment of 3 months. Results: Before treatment

there was no significant difference in the levels of serum calcium (Ca)

phosphate (P)

calcitonin (CT)

vitamin D3 (VitD3)

alkaline phosphatase (ALP) and bone alkaline phosphatase (BAP) between two groups (P>0.05). After treatment of 3 months

the levels of Ca

VitD3 and ALP in the combination group were higher than those in the control group (P<0.05)

and the levels of CT and BAP were lower than those in the control group

the differences were statistically significant (P<0.05). There was no significant difference in the levels of serum P between the combination group and the control group (P>0.05). There were no statistically significant difference in the levels of Ca

P

VitD3

CT and ALP in the combination group before and after treatment (P>0.05)

while there was statistically significant difference in the levels of BAP (P<0.05). After treatment of 3 months

the levels of Ca

VitD3 and ALP in the control group were lower than those before treatment (P<0.05)

and the levels of CT and BAP after treatment were higher than those before treatment

with statistically significant difference (P<0.05). There was no significant difference in the levels of serum P in the control group before and after treatment (P>0.05). Conclusion: Adequate vitamin D supplementation combined with sodium valproate in the treatment of pediatric epilepsy can reduce reduce the abnormal bone metabolism and provide reference for clinical treatment of pediatric epilepsy